Buscar
Mostrando ítems 41-50 de 202
Development Of Biosimilars In BrazilDesenvolvimento De Biossimilares No Brasil
(OpenJournals Publishing, 2016)
Biosimilar monoclonal antibodies in Latin America
(IntechOpen, 2021)
Antibodies, also known as immunoglobulins, are complex glycoproteins produced by B-cells against foreign substances as part of the adaptive immune response [1, 2]. The invention of the hybridoma technology in 1975 by Köhler ...
Worldwide Research Productivity on Biosimilars: A Bibliometric Analysis
(Elsevier Ltd.GB, 2017-10-01)
ABSTRACT
objeCtives: Evaluation of worldwide scientific output on biosimilars has not been explored. Therefore, the objective of this study was to perform a bibliometric overview of global research productivity on ...
Triunfalismo del decreto de biosimilares
(Universidad del Norte, 2014)
O brasil e o panorama regulatório de medicamentos biossimilares - comparação com europa, estados unidos, austrália e canadá
(Universidade Federal de São Paulo, 2022-12-19)
Introdução: A autorização e uso de medicamentos biossimilares é um tema de alta relevância nos últimos anos, desde a aprovação do primeiro biossimilar em 2006 na Europa. Desde então, as agências sanitárias mundiais vêm ...
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
(Biomedicines, 2020-08-23)
Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental ...
Monoclonal antibodies carried in drug delivery nanosystems as a strategy for cancer treatment
(2021-01-01)
Monoclonal antibodies carried in nanosystems have been extensively studied and reported as a promising tool for the treatment of various types of cancers. Monoclonal antibodies have great advantages for the treatment of ...
Impacto presupuestal de tres biosimilares en el sistema de salud colombiano : trastuzumab, infliximab y rituximab
El mercado de medicamentos biológicos constituye una porción significativa del gasto en todos los sistemas de salud. El ingreso de medicamentos biosimilares en muchos países ha mostrado reducir el gasto farmacéutico y ...
Registro sanitario de medicamentos biológicos y biotecnológicos en América Latina
(2021)
Introducción: los medicamentos biológicos se definen como productos cuyos ingredientes activos son producidos por una fuente biológica, mientras que un producto biotecnológico se desarrolla a partir del aislamiento de un ...